{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-016108","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.392545+00:00","generated_at":"2026-05-17T02:09:42.444349+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tonix reports preliminary Q3 net loss $32M, plans Tonmya launch by Nov 2025","bullets":["Preliminary Q3 2025 net loss ~$32.0M vs $14.2M YoY; net revenue $3.3M vs $2.8M.","Cash and equivalents ~$190.1M at Sept 30, 2025; net operating cash use $28.8M.","Subsequent equity offerings net $29.3M; cash runway into Q1 2027.","U.S. commercial launch of Tonmya for fibromyalgia expected by end of Nov 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-016108","json":"https://secwatch.observer/filing/0001999371-25-016108.json","markdown":"https://secwatch.observer/filing/0001999371-25-016108.md","text":"https://secwatch.observer/filing/0001999371-25-016108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125016108/0001999371-25-016108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125016108/tnxp_8k-102725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:09:42.444349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}